Financials Giant Biogene Holding Co., Ltd.

Equities

2367

KYG3887G1091

Personal Products

Market Closed - Hong Kong S.E. 04:08:25 2024-05-30 am EDT 5-day change 1st Jan Change
49.35 HKD -1.10% Intraday chart for Giant Biogene Holding Co., Ltd. -3.71% +38.62%

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 28,963 31,581 46,141 - -
Enterprise Value (EV) 2 27,686 29,210 42,107 40,637 38,852
P/E ratio 30 x 22.2 x 25.3 x 19.9 x 16.3 x
Yield - 1.34% 1.15% 1.47% 1.8%
Capitalization / Revenue 12.2 x 8.96 x 9.84 x 7.67 x 6.16 x
EV / Revenue 11.7 x 8.29 x 8.98 x 6.75 x 5.19 x
EV / EBITDA 23.8 x 17.8 x 20.4 x 15.8 x 12.4 x
EV / FCF 35.5 x 20.6 x 29.8 x 21.6 x 16.6 x
FCF Yield 2.81% 4.87% 3.36% 4.64% 6.01%
Price to Book 10.7 x 7.38 x 8.23 x 6.37 x 5.05 x
Nbr of stocks (in thousands) 976,000 976,000 1,009,220 - -
Reference price 3 33.60 35.60 49.35 49.35 49.35
Announcement Date 3/27/23 3/25/24 - - -
1HKD in Million2CNY in Million3HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 2,364 3,524 4,688 6,018 7,491
EBITDA 1 1,161 1,645 2,067 2,577 3,133
EBIT 1 1,134 1,611 2,026 2,592 3,238
Operating Margin 47.95% 45.71% 43.21% 43.07% 43.22%
Earnings before Tax (EBT) 1 1,178 1,745 2,121 2,698 3,323
Net income 1 1,002 1,452 1,798 2,275 2,792
Net margin 42.38% 41.19% 38.36% 37.8% 37.27%
EPS 2 1.120 1.605 1.949 2.475 3.037
Free Cash Flow 1 779 1,421 1,415 1,884 2,336
FCF margin 32.95% 40.33% 30.18% 31.3% 31.18%
FCF Conversion (EBITDA) 67.1% 86.38% 68.44% 73.11% 74.57%
FCF Conversion (Net income) 77.74% 97.89% 78.68% 82.81% 83.68%
Dividend per Share 2 - 0.4772 0.5678 0.7255 0.8890
Announcement Date 3/27/23 3/25/24 - - -
1CNY in Million2HKD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 1,641 1,606 1,918 2,199 2,582
EBITDA - - - - -
EBIT 1 771.9 714.3 896.7 900.6 1,057
Operating Margin 47.03% 44.49% 46.74% 40.95% 40.95%
Earnings before Tax (EBT) - - 969.5 - -
Net income - - 784.8 - -
Net margin - - 40.91% - -
EPS - - - - -
Dividend per Share - - - - -
Announcement Date 3/27/23 8/28/23 3/25/24 - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - - - - -
Net Cash position 1 1,276 2,371 4,034 5,505 7,289
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 779 1,421 1,415 1,884 2,336
ROE (net income / shareholders' equity) 54.9% 40.8% 34.7% 33.7% 32.1%
ROA (Net income/ Total Assets) 19.2% 36.2% 30.9% 30.6% 29.9%
Assets 1 5,225 4,009 5,815 7,426 9,342
Book Value Per Share 2 3.150 4.820 6.000 7.750 9.770
Cash Flow per Share 2 1.030 1.810 2.300 3.010 3.980
Capex 1 153 226 193 166 178
Capex / Sales 6.46% 6.42% 4.13% 2.75% 2.37%
Announcement Date 3/27/23 3/25/24 - - -
1CNY in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
49.35 HKD
Average target price
55.36 HKD
Spread / Average Target
+12.19%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2367 Stock
  4. Financials Giant Biogene Holding Co., Ltd.